Fate Therapeutics, Inc.
Industry
- Biotechnology
- Gene Therapy, Cell Therapy
- Pharmaceuticals
Other Names/Subsidiaries
- Tfinity Therapeutics
Latest on Fate Therapeutics, Inc.
Radionetics Oncology , a three-year-old start-up that has raised $82.5m to date, landed a sweet deal with Eli Lilly and Company , with the big pharma paying $140m up front for an exclusive right to b
Pfizer Inc. held a 32% stake in Haleon plc after the consumer health business spun out of GSK plc in 2022, but through a sale of stock on 19 March Pfizer reduced its stake to 22.6% and garnered $
There’s a new CAR-T kid on the block. A young Indian cell and gene therapy company, Immunoadoptive Cell Therapy (ImmunoACT), has delivered the country’s first such cell therapy for the treatment of re
More than a year after reporting promising early data for its allogeneic chimeric antigen receptor natural killer (CAR-NK) candidate NKX101 in relapsed/refractory acute myeloid leukemia, Nkarta, Inc.